Literature DB >> 29288202

GM-CSF Promotes Chronic Disability in Experimental Autoimmune Encephalomyelitis by Altering the Composition of Central Nervous System-Infiltrating Cells, but Is Dispensable for Disease Induction.

Patrick C Duncker1,2,3, Joshua S Stoolman1,2,3, Amanda K Huber1,2, Benjamin M Segal4,2,3,5.   

Abstract

GM-CSF has been portrayed as a critical cytokine in the pathogenesis of experimental autoimmune encephalomyelitis (EAE) and, ostensibly, in multiple sclerosis. C57BL/6 mice deficient in GM-CSF are resistant to EAE induced by immunization with myelin oligodendrocyte glycoprotein (MOG)35-55 The mechanism of action of GM-CSF in EAE is poorly understood. In this study, we show that GM-CSF augments the accumulation of MOG35-55-specific T cells in the skin draining lymph nodes of primed mice, but it is not required for the development of encephalitogenic T cells. Abrogation of GM-CSF receptor signaling in adoptive transfer recipients of MOG35-55-specific T cells did not alter the incidence of EAE or the trajectory of its initial clinical course, but it limited the extent of chronic CNS tissue damage and neurologic disability. The attenuated clinical course was associated with a relative dearth of MOG35-55-specific T cells, myeloid dendritic cells, and neutrophils, as well as an abundance of B cells, within CNS infiltrates. Our data indicate that GM-CSF drives chronic tissue damage and disability in EAE via pleiotropic pathways, but it is dispensable during early lesion formation and the onset of neurologic deficits.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29288202      PMCID: PMC5780231          DOI: 10.4049/jimmunol.1701484

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  GM-CSF is not essential for experimental autoimmune encephalomyelitis but promotes brain-targeted disease.

Authors:  Emily R Pierson; Joan M Goverman
Journal:  JCI Insight       Date:  2017-04-06

Review 2.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

3.  Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis.

Authors:  Lionel G Filion; Darius Matusevicius; Gina M Graziani-Bowering; Ashok Kumar; Mark S Freedman
Journal:  Clin Immunol       Date:  2003-02       Impact factor: 3.969

Review 4.  The immunogenetics of multiple sclerosis: A comprehensive review.

Authors:  Jill A Hollenbach; Jorge R Oksenberg
Journal:  J Autoimmun       Date:  2015-07-02       Impact factor: 7.094

5.  Site-specific chemokine expression regulates central nervous system inflammation and determines clinical phenotype in autoimmune encephalomyelitis.

Authors:  Joshua S Stoolman; Patrick C Duncker; Amanda K Huber; Benjamin M Segal
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

6.  IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice.

Authors:  Stefan Haak; Andrew L Croxford; Katharina Kreymborg; Frank L Heppner; Sandrine Pouly; Burkhard Becher; Ari Waisman
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

7.  Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease.

Authors:  Irah L King; Travis L Dickendesher; Benjamin M Segal
Journal:  Blood       Date:  2009-02-05       Impact factor: 22.113

8.  Neutrophil-related factors as biomarkers in EAE and MS.

Authors:  Julie M Rumble; Amanda K Huber; Gurumoorthy Krishnamoorthy; Ashok Srinivasan; David A Giles; Xu Zhang; Lu Wang; Benjamin M Segal
Journal:  J Exp Med       Date:  2015-01-05       Impact factor: 14.307

9.  GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival.

Authors:  Ivo Sonderegger; Giandomenica Iezzi; Reinhard Maier; Nicole Schmitz; Michael Kurrer; Manfred Kopf
Journal:  J Exp Med       Date:  2008-09-08       Impact factor: 14.307

10.  The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease.

Authors:  Thaddeus Carlson; Mark Kroenke; Praveen Rao; Thomas E Lane; Benjamin Segal
Journal:  J Exp Med       Date:  2008-03-17       Impact factor: 14.307

View more
  20 in total

Review 1.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

2.  Deficiency of Socs3 leads to brain-targeted EAE via enhanced neutrophil activation and ROS production.

Authors:  Zhaoqi Yan; Wei Yang; Luke Parkitny; Sara A Gibson; Kevin S Lee; Forrest Collins; Jessy S Deshane; Wayne Cheng; Amy S Weinmann; Hairong Wei; Hongwei Qin; Etty N Benveniste
Journal:  JCI Insight       Date:  2019-04-02

Review 3.  Neuroinflammation: Extinguishing a blaze of T cells.

Authors:  Nail Benallegue; Hania Kebir; Jorge I Alvarez
Journal:  Immunol Rev       Date:  2022-07-31       Impact factor: 10.983

4.  4-Ethylguaiacol modulates neuroinflammation and Th1/Th17 differentiation to ameliorate disease severity in experimental autoimmune encephalomyelitis.

Authors:  Wen-Tsan Weng; Ping-Chang Kuo; Dennis A Brown; Barbara A Scofield; Destin Furnas; Hallel C Paraiso; Pei-Yu Wang; I-Chen Yu; Jui-Hung Yen
Journal:  J Neuroinflammation       Date:  2021-05-11       Impact factor: 8.322

Review 5.  Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis.

Authors:  Jehan Aram; Anna Francis; Radu Tanasescu; Cris S Constantinescu
Journal:  Neurol Ther       Date:  2018-12-01

6.  The hedgehog pathway suppresses neuropathogenesis in CD4 T cell-driven inflammation.

Authors:  Nail Benallegue; Hania Kebir; Richa Kapoor; Alexis Crockett; Cen Li; Lara Cheslow; Mohamed S Abdel-Hakeem; James Gesualdi; Miles C Miller; E John Wherry; Molly E Church; M Andres Blanco; Jorge I Alvarez
Journal:  Brain       Date:  2021-07-28       Impact factor: 13.501

7.  An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE.

Authors:  Joshua S Stoolman; Patrick C Duncker; Amanda K Huber; David A Giles; Jesse M Washnock-Schmid; Athena M Soulika; Benjamin M Segal
Journal:  J Neuroinflammation       Date:  2018-07-16       Impact factor: 8.322

8.  GM-CSF induces noninflammatory proliferation of microglia and disturbs electrical neuronal network rhythms in situ.

Authors:  Hasan Onur Dikmen; Marc Hemmerich; Andrea Lewen; Jan-Oliver Hollnagel; Bruno Chausse; Oliver Kann
Journal:  J Neuroinflammation       Date:  2020-08-11       Impact factor: 8.322

Review 9.  The Diversity of Encephalitogenic CD4+ T Cells in Multiple Sclerosis and Its Animal Models.

Authors:  Benjamin M Segal
Journal:  J Clin Med       Date:  2019-01-19       Impact factor: 4.241

Review 10.  The Role of Granulocyte-Macrophage Colony-Stimulating Factor in Murine Models of Multiple Sclerosis.

Authors:  Kelly L Monaghan; Edwin C K Wan
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.